"Epirubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- 4' Epidoxorubicin
- 4' Epi Doxorubicin
- 4' Epi Adriamycin
- 4' Epiadriamycin
- 4' Epi DXR
Below are MeSH descriptors whose meaning is more general than "Epirubicin".
Below are MeSH descriptors whose meaning is more specific than "Epirubicin".
This graph shows the total number of publications written about "Epirubicin" by people in this website by year, and whether "Epirubicin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Epirubicin" by people in Profiles.
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial. Gastric Cancer. 2019 05; 22(3):577-586.
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017 Apr 01; 35(10):1049-1060.
A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer. Clin Breast Cancer. 2010 Oct 01; 10(5):367-72.
The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study. BMC Cancer. 2009 Jul 11; 9:226.
Circadian rhythm and seasonal dependence in the toxicological response of mice to epirubicin. Invest New Drugs. 1988 Dec; 6(4):273-83.